TNFRSF11A and osteosarcoma: For instance, increased expression of RANK ligand (RANKL) in the RANKL/RANK pathway was associated with poor response of osteosarcoma patients to preoperative chemotherapy and lower cancer‐free survival 6, and specific inhibition of RANK only in osteoclasts abrogated osteosarcoma development 7.